Electra Therapeutics Inc. (NASDAQ: ETRA) Stock Competitors & Peer Comparison
See ETRA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ETRA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ETRA | $13.92 | +5.06% | 295.3M | -5.25 | -$2.65 | N/A |
| RPRX | $58.44 | +0.05% | 25.9B | 11.13 | $5.25 | +1.57% |
| CORT | $113.76 | +3.15% | 12.3B | 325.03 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $78.13 | +1.15% | 6B | 80.55 | $0.97 | N/A |
| LQDA | $66.43 | -0.67% | 5.9B | 48.49 | $1.37 | N/A |
| PBH | $46.80 | +4.07% | 2.2B | 10.59 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $21.11 | -6.39% | 1.3B | -11.41 | -$1.85 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
ETRA vs RPRX Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, RPRX has a market cap of 25.9B. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while RPRX trades at $58.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas RPRX's P/E ratio is 11.13. In terms of profitability, ETRA's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, ETRA is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
ETRA vs CORT Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while CORT trades at $113.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas CORT's P/E ratio is 325.03. In terms of profitability, ETRA's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, ETRA is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
ETRA vs WBA Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas WBA's P/E ratio is -1.64. In terms of profitability, ETRA's ROE is N/A, compared to WBA's ROE of -0.57%. Regarding short-term risk, ETRA is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
ETRA vs KNSA Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while KNSA trades at $78.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas KNSA's P/E ratio is 80.55. In terms of profitability, ETRA's ROE is N/A, compared to KNSA's ROE of +0.14%. Regarding short-term risk, ETRA is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
ETRA vs LQDA Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, LQDA has a market cap of 5.9B. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while LQDA trades at $66.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas LQDA's P/E ratio is 48.49. In terms of profitability, ETRA's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, ETRA is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
ETRA vs PBH Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, PBH has a market cap of 2.2B. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while PBH trades at $46.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas PBH's P/E ratio is 10.59. In terms of profitability, ETRA's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, ETRA is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
ETRA vs HROWL Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas HROWL's P/E ratio is N/A. In terms of profitability, ETRA's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, ETRA is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
ETRA vs HROWM Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas HROWM's P/E ratio is N/A. In terms of profitability, ETRA's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, ETRA is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
ETRA vs LTGO Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while LTGO trades at $21.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas LTGO's P/E ratio is -11.41. In terms of profitability, ETRA's ROE is N/A, compared to LTGO's ROE of N/A. Regarding short-term risk, ETRA is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check LTGO's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
ETRA vs HELP Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, HELP has a market cap of 846.7M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while HELP trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas HELP's P/E ratio is -3.28. In terms of profitability, ETRA's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, ETRA is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
ETRA vs SVA Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas SVA's P/E ratio is -5.68. In terms of profitability, ETRA's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, ETRA is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
ETRA vs CUVL Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, CUVL has a market cap of 293.5M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while CUVL trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas CUVL's P/E ratio is 12.56. In terms of profitability, ETRA's ROE is N/A, compared to CUVL's ROE of N/A. Regarding short-term risk, ETRA is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
ETRA vs CELG-RI Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, CELG-RI has a market cap of 254.5M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, ETRA's ROE is N/A, compared to CELG-RI's ROE of N/A. Regarding short-term risk, ETRA is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
ETRA vs HITI Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, HITI has a market cap of 231.1M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while HITI trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas HITI's P/E ratio is -9.71. In terms of profitability, ETRA's ROE is N/A, compared to HITI's ROE of -0.36%. Regarding short-term risk, ETRA is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check HITI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
ETRA vs CTOR Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, CTOR has a market cap of 97.2M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while CTOR trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas CTOR's P/E ratio is -2.22. In terms of profitability, ETRA's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, ETRA is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
ETRA vs ATLN Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas ATLN's P/E ratio is -0.68. In terms of profitability, ETRA's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, ETRA is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check ATLN's competition here
Stablecoin Development Corp. (AMEX: SDEV)
ETRA vs SDEV Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, SDEV has a market cap of 49.1M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while SDEV trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas SDEV's P/E ratio is -0.17. In terms of profitability, ETRA's ROE is N/A, compared to SDEV's ROE of +7.90%. Regarding short-term risk, ETRA is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
ETRA vs RAD Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas RAD's P/E ratio is -0.05. In terms of profitability, ETRA's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, ETRA is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
ETRA vs GLTO Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas GLTO's P/E ratio is -1.78. In terms of profitability, ETRA's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, ETRA is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
ETRA vs NSRX Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, NSRX has a market cap of 29.6M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while NSRX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas NSRX's P/E ratio is -4.78. In terms of profitability, ETRA's ROE is N/A, compared to NSRX's ROE of -1.59%. Regarding short-term risk, ETRA is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
ETRA vs SCYX Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, SCYX has a market cap of 27.7M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while SCYX trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas SCYX's P/E ratio is -1.29. In terms of profitability, ETRA's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, ETRA is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
ETRA vs COSM Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, COSM has a market cap of 18.4M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while COSM trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas COSM's P/E ratio is -0.46. In terms of profitability, ETRA's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, ETRA is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check COSM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
ETRA vs BFRI Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, BFRI has a market cap of 14.9M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while BFRI trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas BFRI's P/E ratio is -2.11. In terms of profitability, ETRA's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, ETRA is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
ETRA vs CNSY Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, CNSY has a market cap of 13.1M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while CNSY trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas CNSY's P/E ratio is -0.45. In terms of profitability, ETRA's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, ETRA is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check CNSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
ETRA vs SCNX Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, SCNX has a market cap of 12.4M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while SCNX trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas SCNX's P/E ratio is -0.15. In terms of profitability, ETRA's ROE is N/A, compared to SCNX's ROE of -0.54%. Regarding short-term risk, ETRA is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check SCNX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
ETRA vs BFRIW Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, BFRIW has a market cap of 11.6M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, ETRA's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, ETRA is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check BFRIW's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
ETRA vs CJJD Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas CJJD's P/E ratio is -0.46. In terms of profitability, ETRA's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, ETRA is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
ETRA vs SSY Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas SSY's P/E ratio is -2.86. In terms of profitability, ETRA's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, ETRA is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
ETRA vs POM Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while POM trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas POM's P/E ratio is -0.13. In terms of profitability, ETRA's ROE is N/A, compared to POM's ROE of +0.16%. Regarding short-term risk, ETRA is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
ETRA vs BGMS Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, BGMS has a market cap of 5.3M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while BGMS trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas BGMS's P/E ratio is -0.27. In terms of profitability, ETRA's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, ETRA is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check BGMS's competition here
Eocene Ltd. (NASDAQ: EOCN)
ETRA vs EOCN Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, EOCN has a market cap of 3.6M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while EOCN trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas EOCN's P/E ratio is -0.25. In terms of profitability, ETRA's ROE is N/A, compared to EOCN's ROE of N/A. Regarding short-term risk, ETRA is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
ETRA vs PAVS Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, PAVS has a market cap of 3.5M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while PAVS trades at $4.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas PAVS's P/E ratio is -0.05. In terms of profitability, ETRA's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, ETRA is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
ETRA vs MDVL Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas MDVL's P/E ratio is -0.05. In terms of profitability, ETRA's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, ETRA is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
ETRA vs ATNFW Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas ATNFW's P/E ratio is N/A. In terms of profitability, ETRA's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, ETRA is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
ETRA vs BGMSP Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, ETRA's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, ETRA is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
ETRA vs AZNH Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas AZNH's P/E ratio is 38.35. In terms of profitability, ETRA's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, ETRA is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
ETRA vs LFLYW Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, ETRA's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, ETRA is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
ETRA vs PRPH Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, PRPH has a market cap of 148.9K. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas PRPH's P/E ratio is N/A. In terms of profitability, ETRA's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, ETRA is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
ETRA vs CPD Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, CPD has a market cap of 0. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas CPD's P/E ratio is N/A. In terms of profitability, ETRA's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, ETRA is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check CPD's competition here
Shire plc (NASDAQ: SHPG)
ETRA vs SHPG Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas SHPG's P/E ratio is 11.35. In terms of profitability, ETRA's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, ETRA is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check SHPG's competition here
POZEN Inc. (NASDAQ: POZN)
ETRA vs POZN Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, POZN has a market cap of 0. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas POZN's P/E ratio is N/A. In terms of profitability, ETRA's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, ETRA is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check POZN's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
ETRA vs OREX Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, OREX has a market cap of 0. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas OREX's P/E ratio is -0.14. In terms of profitability, ETRA's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, ETRA is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check OREX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
ETRA vs IPXL Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas IPXL's P/E ratio is -10.11. In terms of profitability, ETRA's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, ETRA is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for ETRA.Check IPXL's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
ETRA vs ESRX Comparison September 2026
Electra Therapeutics Inc. (NASDAQ: ETRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ETRA stands at 295.3M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, ETRA is priced at $13.92 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ETRA currently has a P/E ratio of -5.25, whereas ESRX's P/E ratio is 10.69. In terms of profitability, ETRA's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, ETRA is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for ETRA.Check ESRX's competition here